This study, involving patients with early rheumatoid arthritis, found that treatment regimens combining methotrexate and glucocorticoids, with or without initial high-dose methylprednisolone, showed higher remission rates over one year compared to methotrexate or leflunomide alone, and all regimens were generally well-tolerated.
4 citations
,
June 2013 in “The Journal of Rheumatology” This abstract describes a program with various presentations and events focused on Canadian excellence in rheumatology but reports no new research findings.
March 2010 in “Anti-inflammatory & anti-allergy agents in medicinal chemistry” This review details the adverse effects and drug interactions of biologic agents used in rheumatoid disease treatment, highlighting their significant side effect profile without reporting new clinical findings.
January 2018 in “Practical diabetes” In this study, leflunomide was effective in treating rheumatoid arthritis, showing comparable efficacy to methotrexate and greater response rates than sulfasalazine, but has significant side effects that require monitoring.
37 citations
,
September 2017 in “Reumatología Clínica” In this systematic review and meta-analysis, methotrexate and leflunomide were compared for treating rheumatoid arthritis, showing similar efficacy overall. Methotrexate reduced swollen joints more effectively, while leflunomide was associated with fewer gastrointestinal side effects but more frequent liver enzyme increases.
